Phase I/II study of RGX-121 in pediatric patients with Mucopolysaccharidosis Type II (MPS II)

Trial Profile

Phase I/II study of RGX-121 in pediatric patients with Mucopolysaccharidosis Type II (MPS II)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs RGX 121 (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Jan 2018 According to a Regenxbio media release, interim update from this trial is expected in late 2018.
    • 22 Dec 2017 Planned number of patients changed to 6.
    • 19 Dec 2017 According to a Regenxbio media release, the Investigational New Drug application (IND) is active for this planned trial, and the trial enrollment is expected to begin during the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top